Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer

NCT04397601 · clinicaltrials.gov ↗

UNKNOWN

Status

220

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Folfiri/Bevacizumab
DRUG: Folfiri/Aflibercept

Sponsor

National Cancer Institute, Naples